Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.38 |
| ▸ | LMNA | P02545 | 1/20 | 0.35 |
| ▸ | MAPT | P10636 | 1/20 | 0.35 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.34 |
| ▸ | CNR2 | P34972 | 11/20 | 0.33 |
| ▸ | TLR4 | O00206 | 1/20 | 0.33 |
| ▸ | HMGCR | P04035 | 1/20 | 0.32 |
| ▸ | CNR1 | P21554 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24326027 | 0.87 | CNR2 (0.34) | LMNACNR2 | |
| SCHEMBL26358020 | 0.83 | ALDH1A1 (0.38) | ALDH1A1KMT2ALMNAMAPTCYP2C9 | |
| SCHEMBL24325628 | 0.81 | ALDH1A1 (0.48) | ALDH1A1KMT2ALMNAMAPTCNR2 | |
| SCHEMBL24326600 | 0.80 | CYP2C9 (0.39) | ALDH1A1KMT2ALMNAMAPTCYP2C9 | |
| SCHEMBL6750673 | 0.74 | TLR4 (0.38) | ALDH1A1KMT2ALMNAMAPTCYP2C9 | |
| SCHEMBL21243382 | 0.73 | TRPM8 (0.36) | ALDH1A1KMT2ALMNAMAPTCYP2C9 | |
| SCHEMBL14144838 | 0.73 | PRKCA (0.38) | LMNACNR2CNR1 | |
| SCHEMBL30457829 | 0.73 | MAPT (0.38) | ALDH1A1KMT2ALMNAMAPTCYP2C9 | |
| SCHEMBL13561251 | 0.72 | HMGCR (0.44) | LMNACNR2HMGCRCNR1 | |
| SCHEMBL4763677 | 0.71 | HCAR2 (0.36) | ALDH1A1LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220119426-A1 | PRODRUGS OF PHOSPHONAMIDE NUCLEOTIDE ANALOGUES AND THEIR PHARMACEUTICAL USE | GILEAD SCIENCES, INC. | 2022-04-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220119426-A1 | PRODRUGS OF PHOSPHONAMIDE NUCLEOTIDE ANALOGUES AND THEIR PHARMACEUTICAL USE | PNP, TYMP, NME2 | ALDH1A1 3872/4885KMT2A 4151/4885LMNA 1373/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.